ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

Abstract Background Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is incurable, with a median survival of only ~ 13 months. We have initiated the randomized placebo-controlled phase IIb st...

ver descrição completa

Detalhes bibliográficos

Principais autores:	J. A. Kyte, A. Røssevold, R. S. Falk, B. Naume
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-06-01
coleção:	Journal of Translational Medicine
Assuntos:	Breast cancer Triple negative Immunotherapy Checkpoint inhibitor Immunogenic cell death PD-1
Acesso em linha:	http://link.springer.com/article/10.1186/s12967-020-02424-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!